Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00796484 · ClinicalTrials.gov registry record · Phase 1
Safety Study of Pharmacokinetics of XL888 in Adults With Solid Tumors
A Phase 1 study, sponsored by Exelixis.
- Terminated
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT00796484 is a Phase 1 study that was terminated before completion, run by Exelixis. The registered enrollment target is 33 participants.
The verdict
NCT00796484, a Phase 1 study, was terminated before completion, sponsored by Exelixis.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability of XL888 in subjects with solid tumors. XL888 is a potent and selective inhibitor of HSP90, a key component of a molecular chaperone complex that promotes the conformational maturation and stabilization of diverse client proteins. Many HSP90 client proteins play critical roles in signaling pathways implicated in tumor cell growth, proliferation, and survival.
Interventions
- DRUG XL888
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2008-11 |
| Est. Completion | 2010-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00796484
The ClinicalTrials.gov registry entry for NCT00796484 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Exelixis, which has 48 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which XL888 is the first listed.
NCT00796484 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00796484 about?
NCT00796484 is a clinical study titled "Safety Study of Pharmacokinetics of XL888 in Adults With Solid Tumors". The purpose of this study is to evaluate the safety and tolerability of XL888 in subjects with solid tumors. XL888 is a potent and selective inhibitor of HSP90, a key component of a molecular chaperone complex that promotes the conformational maturation and stabilization of diverse client proteins. ...
What is the current status of trial NCT00796484?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2008-11. Estimated completion is 2010-11.
What interventions are being tested in trial NCT00796484?
The interventions under investigation include: XL888 (DRUG).
Who is sponsoring clinical trial NCT00796484?
This trial is sponsored by Exelixis, which has 48 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.